Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical ...
Emergent BioSolutionsDecember 29, 2020 GMT
GAITHERSBURG, Md. and NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate Emergent’s COVID-19 Human Hyperimmune Globulin (COVID-HIG) product candidate in the first of two Phase 1 studies to support its use for potential post-exposure prophylaxis in individuals at high risk of exposure to SARS-CoV-2, the virus that causes COVID-19, such as front-line health care workers and military personnel.